Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions ...

In a paradigm-breaking study, researchers have discovered a novel way the immune system, specifically T cells, attack their target cells, reshaping long-held assumptions in immunology and ...

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ...

Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

The immune system exhibits remarkable plasticity, enabling dynamic responses to environmental cues while maintaining tissue homeostasis. Emerging evidence ...

Across the immunity cycle, NPs can co-deliver tumor antigens and adjuvants to DCs, enhance major histocompatibility complex class I (MHC-I)-mediated cross-presentation, and promote cytotoxic T ...

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual ...

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...